<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155257</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00028525</org_study_id>
    <nct_id>NCT02155257</nct_id>
  </id_info>
  <brief_title>Pain Expectations in Subjects With Osteoarthritis</brief_title>
  <official_title>A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test whether or not researchers can alter or change
      expectations on pain. The researchers will test whether there is an effect on the size of the
      pupil and responses to thermal heat temperatures in subjects with osteoarthritis of the knee
      or hip or healthy subjects for comparison.

      One of 3 possible treatment groups will be administered to qualifying subjects: (1)
      gabapentin, a medication that is commonly used to treat nerve pain, (2) modafinil, a
      medication that is commonly used to treat people with narcolepsy (a disorder that causes
      people to fall asleep) and (3) a placebo, which is an inactive substance, like a sugar pill,
      that is not thought to have any effect on your disease or condition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose and rationale for this study: Both chronic pain and disability after total knee
      replacement surgery are predicted by negative cognitive-affective state, characterized by
      depression, anxiety, and a cognitive style dominated by catastrophizing. How this negative
      state results in chronic pain and disability is not known, but we hypothesize that it causes
      dysfunction of the release of the neurotransmitter, norepinephrine in several regions of the
      brain, mid-brain, and spinal cord that are important to many processes involved in recovery
      from surgery.

      Objectives: (1) Gabapentin and modafinil will increase resting pupil diameter with a moderate
      effect size in patients with osteoarthritis; (2) Expectations will modify pain experience
      with a moderate effect size in these patients

      Methods: 30 subjects with moderate average daily pain from osteoarthritis of the knee or hip
      or healthy subjects will be recruited and will come to the clinical research unit at Wake
      Forest. Informed consent will be confirmed and they will complete the questionnaires. We will
      take a verbal medical and medication history and obtain blood pressure and heart rate
      measurements. Verbal pain intensity report (0-10 from no pain to worst pain imaginable) will
      be obtained from a 5 second heat stimuli, separated by 30 seconds, delivered to a nonpainful
      area of skin on the arm as described in preliminary data. During pain testing, study subjects
      will sit in a comfortable chair in a low-ambient light room with their head positioned on a
      chin rest for continuous recording of pupil diameter using a near infrared recording system
      as described in preliminary data. Pupil diameter and probe temperature will be passed through
      an analog to digital converter and acquired at 60 Hertz (Hz) for subsequent analysis.

      Five sequences of test stimuli will be presented, with a brief break in between each
      sequence. The first sequence will consist of 7 stimuli, from 39⁰ to 51⁰ Celsius (C) in 2⁰C
      increments, in ascending order. Data from this training sequence will not be used for
      analysis. Sequences 2 and 3 will consist of 5, 5-second stimuli, presented in random order,
      to generate moderate (50⁰C) and mild (47⁰C) pain (random condition). Sequences 4 and 5 will
      also consist of random presentation of 5 stimuli at these temperatures, but with different
      auditory tones 6 s prior to stimulus onset to correctly cue the stimulus temperature (cued
      condition).

      Subjects will then be randomized to receive oral gabapentin, 900 milligram (mg), modafinil,
      200 mg, or placebo, followed 2 hours later by pain testing with pupillometry, consisting of
      different sequences. The random and cued paradigms will be presented twice each followed by a
      sequence with one miscue in the positive expectation for pain direction (signal for 50⁰C but
      deliver 47⁰C) and one in the negative expectation for pain direction. Subjects will provide
      verbal pain intensity scores after each stimulus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resting Pupil Diameter</measure>
    <time_frame>Baseline and 2 hours</time_frame>
    <description>Resting pupil diameter will be measured using an infrared camera to obtain baseline measurements 2 hours after dosing subject pupil diameter measurements will be repeated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Rating</measure>
    <time_frame>Reported 5 seconds after each stimulus</time_frame>
    <description>Pain is reported verbally after each stimulus by the subject on a scale of 0 (no pain) to 10 (worst imagineable pain). For each individual the value used is the average of all presentations of the 50 degree stimulus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Style</measure>
    <time_frame>baseline</time_frame>
    <description>Cognitive style determined for each individual by subtracting the score in the Pain Catastrophizing Scale (CATS) questionnaire (with a score range of 0-52 with higher score showing more catastrophizing) from the Life Orientation Test Revised (LOT-R) questionnaire (score range of 0-24, with a higher score denoting a better outcome). Thus, the total score could range from ranges from -52 to 24, with lower scores indicating worse cognitive style related to pain reporting and higher scores indicating better cognitive style related to pain reporting. There are no subscales here.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Modafinil 200 mg will be administered orally one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo will be administered orally one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gabapentin 900 mg will be administered orally one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <arm_group_label>Modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoarthritis of the knee or hip

          -  Adult (ages 18-80)

          -  Moderate pain (verbal score of ≥ 4 ≤ 7 on 0-10 scale for average pain intensity with
             normal activity)

          -  American Society of Anesthesiologists physical status 1-3

          -  Healthy subjects without pain

        Exclusion Criteria:

          -  Pregnancy;

          -  Currently taking gabapentin

          -  Currently taking a narcotic prescription medication that is &gt; 50 mg morphine
             equivalents/day

          -  Advanced or unstable cardiac, pulmonary, renal or hepatic dysfunction

          -  History of previous eye surgery

          -  Psychotic disorder or a recent psychiatric hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Eisenach, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <results_first_submitted>November 7, 2018</results_first_submitted>
  <results_first_submitted_qc>February 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2019</results_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee pain</keyword>
  <keyword>Hip pain</keyword>
  <keyword>Total Knee Replacement Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02155257/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02155257/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Modafinil</title>
          <description>Modafinil 200 mg will be administered orally one time
Modafinil</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>A placebo will be administered orally one time
Placebo</description>
        </group>
        <group group_id="P3">
          <title>Gabapentin</title>
          <description>Gabapentin 900 mg will be administered orally one time
Gabapentin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modafinil</title>
          <description>Modafinil 200 mg will be administered orally one time
Modafinil</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A placebo will be administered orally one time
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Gabapentin</title>
          <description>Gabapentin 900 mg will be administered orally one time
Gabapentin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Resting Pupil Diameter</title>
        <description>Resting pupil diameter will be measured using an infrared camera to obtain baseline measurements 2 hours after dosing subject pupil diameter measurements will be repeated</description>
        <time_frame>Baseline and 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil 200 mg will be administered orally one time
Modafinil</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A placebo will be administered orally one time
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Gabapentin</title>
            <description>Gabapentin 900 mg will be administered orally one time
Gabapentin</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Pupil Diameter</title>
          <description>Resting pupil diameter will be measured using an infrared camera to obtain baseline measurements 2 hours after dosing subject pupil diameter measurements will be repeated</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="11.5"/>
                    <measurement group_id="O2" value="72" spread="12.6"/>
                    <measurement group_id="O3" value="69" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="11.9"/>
                    <measurement group_id="O2" value="70.9" spread="14.5"/>
                    <measurement group_id="O3" value="66.1" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Interaction between resting pupil diameter and correlation of cognitive-affective style to pain reporting. Note that this analysis is an INTERACTION between the primary outcome of this measure (pupil diameter) to that of the primary outcome measure of cognitive-affective style.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.540</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.39</ci_lower_limit>
            <ci_upper_limit>.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Rating</title>
        <description>Pain is reported verbally after each stimulus by the subject on a scale of 0 (no pain) to 10 (worst imagineable pain). For each individual the value used is the average of all presentations of the 50 degree stimulus.</description>
        <time_frame>Reported 5 seconds after each stimulus</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil 200 mg will be administered orally one time
Modafinil</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A placebo will be administered orally one time
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Gabapentin</title>
            <description>Gabapentin 900 mg will be administered orally one time
Gabapentin</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Rating</title>
          <description>Pain is reported verbally after each stimulus by the subject on a scale of 0 (no pain) to 10 (worst imagineable pain). For each individual the value used is the average of all presentations of the 50 degree stimulus.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.7"/>
                    <measurement group_id="O2" value="2.8" spread="1.8"/>
                    <measurement group_id="O3" value="2.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Style</title>
        <description>Cognitive style determined for each individual by subtracting the score in the Pain Catastrophizing Scale (CATS) questionnaire (with a score range of 0-52 with higher score showing more catastrophizing) from the Life Orientation Test Revised (LOT-R) questionnaire (score range of 0-24, with a higher score denoting a better outcome). Thus, the total score could range from ranges from -52 to 24, with lower scores indicating worse cognitive style related to pain reporting and higher scores indicating better cognitive style related to pain reporting. There are no subscales here.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil 200 mg will be administered orally one time
Modafinil</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A placebo will be administered orally one time
Placebo</description>
          </group>
          <group group_id="O3">
            <title>Gabapentin</title>
            <description>Gabapentin 900 mg will be administered orally one time
Gabapentin</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Style</title>
          <description>Cognitive style determined for each individual by subtracting the score in the Pain Catastrophizing Scale (CATS) questionnaire (with a score range of 0-52 with higher score showing more catastrophizing) from the Life Orientation Test Revised (LOT-R) questionnaire (score range of 0-24, with a higher score denoting a better outcome). Thus, the total score could range from ranges from -52 to 24, with lower scores indicating worse cognitive style related to pain reporting and higher scores indicating better cognitive style related to pain reporting. There are no subscales here.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="2.3"/>
                    <measurement group_id="O2" value="15.5" spread="2.3"/>
                    <measurement group_id="O3" value="14.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Modafinil</title>
          <description>Modafinil 200 mg will be administered orally one time
Modafinil</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A placebo will be administered orally one time
Placebo</description>
        </group>
        <group group_id="E3">
          <title>Gabapentin</title>
          <description>Gabapentin 900 mg will be administered orally one time
Gabapentin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Eisenach</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>3367164182</phone>
      <email>eisenach@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

